Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity

Wang,Wan‑Peng; Gao,Hai‑Ying

doi:10.3892/etm.2017.5505

Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity

Authors:
- Wan‑Peng Wang
- Hai‑Ying Gao
View Affiliations

Affiliations: Department of Infectious Diseases, Weifang City People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: November 13, 2017 https://doi.org/10.3892/etm.2017.5505
Pages: 641-648
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Avoidance of apoptosis induced by anticancer drugs is an essential factor of carcinogenesis and a hallmark of resistance to cancer therapy. Human telomerase reverse transcriptase receptor (hTERTR) is a potential anti‑cancer agent for inhibiting tumor growth. Family with sequence similarity 96 member A (FAM96A) is a ubiquitous, conserved protein and possesses apoptosome‑activating and pro‑apoptotic tumor suppressor potential in hepatocellular carcinoma (HCC). In the present study, hTERTR and FAM96A were identified as efficient anti‑cancer agents for activating apoptosomes and reducing tumor growth. The potential tumor suppressor function of combination treatment with hTERTR and FAM96A in HCC was also investigated. hTERTR and FAM96A proteins were expressed by genetic engineering and their anti‑cancer function was explored in vitro and in vivo. Effects of hTERTR and FAM96A on improvement of apoptotic sensitivity and inhibition of migration and invasion were examined in cancer cells and in a mouse model. The present results demonstrated that the therapeutic effects of hTERTR and FAM96A were effective for inhibiting tumor growth and inducing apoptosis of HCC cells in H22‑bearing nude mice compared with single agent treatment. hTERTR and FAM96A were found to bind with apoptotic protease activating factor 1 and human telomerase reverse transcriptase, which enhanced the apoptosis of tumor cells and apoptosis sensitivity. In addition, hTERTR and FAM96A therapy enhanced cytotoxic effects by cytotoxic T lymphocyte responses, interferon‑γ release, T lymphocytes infiltration and apoptosis on tumor cells. Furthermore, hTERTR and FAM96A protein inhibited tumor growth in HCC mice. In conclusion, the present findings suggested that combination therapy with hTERTR and FAM96A may serve as novel tumor suppressor agents.

View Figures

View References

1	Fung SK and Lok AS: Management of patients with hepatitis B virus-induced cirrhosis. J Hepatol. 42 Suppl:S54–S64. 2005. View Article : Google Scholar : PubMed/NCBI
2	Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, Lee PC, Chang FY and Lee SD: Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther. 23:129–135. 2006. View Article : Google Scholar : PubMed/NCBI
3	Devlin EJ, Denson LA and Whitford HS: Cancer treatment side effects: A Meta-analysis of the relationship between response expectancies and experience. J Pain Symptom Manage. 54:245–258.e2. 2017. View Article : Google Scholar : PubMed/NCBI
4	Kudo K and Nakagawa K: Management of side effects with platinum doublet chemotherapy used for treatment of non-small cell lung cancer. Nihon Rinsho. 73 Suppl 2:S542–S547. 2015.(In Japanese).
5	Vincent J, de Boer M, Lobbezoo DJ, Smeets RE and Tjan-Heijnen VC: Combination of exemestane and everolimus may produce toxic side effects: A new treatment option for metastatic hormone-sensitive breast cancer. Ned Tijdschr Geneeskd. 158:A75232014.(In Dutch). PubMed/NCBI
6	Lubienski A, Bitsch RG, Schemmer P, Grenacher L, Düx M and Kauffmann GW: Long-term results of interventional treatment of large unresectable hepatocellular carcinoma (HCC): Significant survival benefit from combined transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) compared to TACE monotherapy. Rofo. 176:1794–1802. 2004. View Article : Google Scholar : PubMed/NCBI
7	Yeh ML, Huang CI, Huang CF, Hsieh MY, Huang JF, Dai CY, Lin ZY, Chen SC, Yu ML and Chuang WL: Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. Kaohsiung J Med Sci. 31:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
8	Guo Z, Yu H, Liu C, Si T, Yang X, Zhang W, Xu Y and Li Y: Advances in endovascular therapy to treat primary hepatocellular carcinoma. Drug Discov Ther. 9:342–351. 2015. View Article : Google Scholar : PubMed/NCBI
9	Jiang J, Yu C, Chen M, Tian S and Sun C: Over-expression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/β-catenin signaling. Biochem Biophys Res Commun. 464:1120–1127. 2015. View Article : Google Scholar : PubMed/NCBI
10	Mizukoshi E, Nakagawa H, Kitahara M, Yamashita T, Arai K, Sunagozaka H, Iida N, Fushimi K and Kaneko S: Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. Cancer Lett. 369:242–249. 2015. View Article : Google Scholar : PubMed/NCBI
11	Ibrahim AA, Abdel Aleem MH, Abdella HM and Helmy A: Study of the role of insulin resistance as a risk factor in HCV related hepatocellular carcinoma. J Egypt Soc Parasitol. 45:107–113. 2015. View Article : Google Scholar : PubMed/NCBI
12	Huang TS, Shyu YC, Chen HY, Yuan SS, Shih JN and Chen PJ: A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma. J Viral Hepat. 20:729–743. 2013. View Article : Google Scholar : PubMed/NCBI
13	Park YJ, Kim EK, Bae JY, Moon S and Kim J: Human telomerase reverse transcriptase (hTERT) promotes cancer invasion by modulating cathepsin D via early growth response (EGR)-1. Cancer Lett. 370:222–231. 2016. View Article : Google Scholar : PubMed/NCBI
14	Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, et al: Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther. 2:539–544. 2000. View Article : Google Scholar : PubMed/NCBI
15	Stehling O, Mascarenhas J, Vashisht AA, Sheftel AD, Niggemeyer B, Rösser R, Pierik AJ, Wohlschlegel JA and Lill R: Human CIA2A-FAM96A and CIA2B-FAM96B integrate iron homeostasis and maturation of different subsets of cytosolic-nuclear iron-sulfur proteins. Cell Metab. 18:187–198. 2013. View Article : Google Scholar : PubMed/NCBI
16	Mas C, Chen KE, Brereton IM, Martin JL and Hill JM: Backbone resonance assignments of the monomeric DUF59 domain of human Fam96a. Biomol NMR Assign. 7:117–120. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chen KE, Richards AA, Ariffin JK, Ross IL, Sweet MJ, Kellie S, Kobe B and Martin JL: The mammalian DUF59 protein Fam96a forms two distinct types of domain-swapped dimer. Acta Crystallogr D Biol Crystallogr. 68:637–648. 2012. View Article : Google Scholar : PubMed/NCBI
18	Ouyang B, Wang L, Wan S, Luo Y, Lin J and Xia B: Solution structure of monomeric human FAM96A. J Biomol NMR. 56:387–392. 2013. View Article : Google Scholar : PubMed/NCBI
19	Hawkins P, Morton DB, Burman O, Dennison N, Honess P, Jennings M, Lane S, Middleton V, Roughan JV, Wells S and Westwood K; UK Joint Working Group on Refinement BVAAWF/FRAME/RSPCA/UFAW, : A guide to defining and implementing protocols for the welfare assessment of laboratory animals: Eleventh report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. Lab Anim. 45:1–13. 2011. View Article : Google Scholar : PubMed/NCBI
20	Morotomi N, Fukuda K, Nakano M, Ichihara S, Oono T, Yamazaki T, Kobayashi N, Suzuki T, Tanaka Y and Taniguchi H: Evaluation of intestinal microbiotas of healthy Japanese adults and effect of antibiotics using the 16S ribosomal RNA gene based clone library method. Biol Pharm Bull. 34:1011–1020. 2011. View Article : Google Scholar : PubMed/NCBI
21	Liang X, Zhang H, Zhang E, Wei J, Li W, Wang B, Dong S and Zhu J: Identification of the pXO1 plasmid in attenuated Bacillus anthracis vaccine strains. Virulence. 7:578–586. 2016. View Article : Google Scholar : PubMed/NCBI
22	Greaves MF and Brown G: Purification of human T and B lymphocytes. J Immunol. 112:420–423. 1974.PubMed/NCBI
23	Zamarin D, Vigil A, Kelly K, Garcia-Sastre A and Fong Y: Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 16:796–804. 2009. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX and Tang ZY: Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res. 15:4838–4846. 2009. View Article : Google Scholar : PubMed/NCBI
26	Hons JM: New insights into the immunomodulatory effects of exercise and potential Impact on tumorigenesis. Oncology (Williston Park). 29:921–922. 2015.PubMed/NCBI
27	Aldinucci D, Celegato M and Casagrande N: Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance. Cancer Lett. 380:243–252. 2016. View Article : Google Scholar : PubMed/NCBI
28	Webb TE and Galli A: Hepatocellular carcinoma cells that develop resistance to the telomerase-activated prodrug ACV-TP-T may undergo spontaneous apoptosis. Med Hypotheses. 85:3832015. View Article : Google Scholar : PubMed/NCBI
29	Mundt HM, Stremmel W, Melino G, Krammer PH, Schilling T and Müller M: Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem Biophys Res Commun. 396:335–341. 2010. View Article : Google Scholar : PubMed/NCBI
30	Jablonski EM, Mattocks MA, Sokolov E, Koniaris LG, Hughes FM Jr, Fausto N, Pierce RH and McKillop IH: Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma. Cancer Lett. 250:36–46. 2007. View Article : Google Scholar : PubMed/NCBI
31	Mizuno H, Honda M, Shirasaki T, Yamashita T, Mizukoshi E and Kaneko S: Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma. Liver Int. 32:1146–1155. 2012. View Article : Google Scholar : PubMed/NCBI
32	Masutomi K, Kaneko S, Yasukawa M, Arai K, Murakami S and Kobayashi K: Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma. Oncogene. 21:5946–5950. 2002. View Article : Google Scholar : PubMed/NCBI
33	Kim YH, Kim KT, Lee SJ, Hong SH, Moon JY, Yoon EK, Kim S, Kim EO, Kang SH, Kim SK, et al: Image-aided suicide gene therapy utilizing multifunctional hTERT-targeting adenovirus for clinical translation in hepatocellular carcinoma. Theranostics. 6:357–368. 2016. View Article : Google Scholar : PubMed/NCBI
34	Schwamb B, Pick R, Fernández SB, Völp K, Heering J, Dötsch V, Bösser S, Jung J, Beinoraviciute-Kellner R, Wesely J, et al: FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors. Int J Cancer. 137:1318–1329. 2015. View Article : Google Scholar : PubMed/NCBI
35	Sacco PC, Maione P, Rossi A, Bareschino MA, Schettino C, Guida C, Elmo M, Ambrosio R, Barbato V, Zeppa R, et al: Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Target Oncol. 6:171–180. 2011. View Article : Google Scholar : PubMed/NCBI
36	Batist G, Wu JH, Spatz A, Miller WH Jr, Cocolakis E, Rousseau C, Diaz Z, Ferrario C and Basik M: Resistance to cancer treatment: The role of somatic genetic events and the challenges for targeted therapies. Front Pharmacol. 2:592011. View Article : Google Scholar : PubMed/NCBI
37	Aggarwal R and Ryan CJ: Castration-resistant prostate cancer: Targeted therapies and individualized treatment. Oncologist. 16:264–275. 2011. View Article : Google Scholar : PubMed/NCBI
38	Rivera F, Lopez-Tarruella S, Vega-Villegas ME and Salcedo M: Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. 35:335–339. 2009. View Article : Google Scholar : PubMed/NCBI
39	Bunn PA Jr and Kelly K: Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Clin Lung Cancer. 2 Suppl 1:S23–S28. 2000. View Article : Google Scholar : PubMed/NCBI
40	Cabrespine A, Bay JO, Barthomeuf C, Curé H, Chollet P and Debiton E: In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment. Anticancer Drugs. 16:417–422. 2005. View Article : Google Scholar : PubMed/NCBI
41	Lee BS, Kim HJ, Hwang JW, Cheong KH, Kim KA, Cha HY, Lee JM and Kim CH: The dual inhibition of Met and EGFR by ME22S, a novel Met/EGFR bispecific monoclonal antibody, suppresses the proliferation and invasion of laryngeal cancer. Ann Surg Oncol. 23:2046–2053. 2016. View Article : Google Scholar : PubMed/NCBI
42	Taki S, Kamada H, Inoue M, Nagano K, Mukai Y, Higashisaka K, Yoshioka Y, Tsutsumi Y and Tsunoda S: A novel bispecific antibody against human CD3 and ephrin receptor A10 for breast cancer therapy. PLoS One. 10:e01447122015. View Article : Google Scholar : PubMed/NCBI